Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic mesenchymal stem cells for neuropathic diabetic foot ulcer
IRCT20170612034485N2Phase 2Completed
- Sponsor
- ACECR
- Start
- Mar 2019
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MSV alogénicas in diabetic foot ulcer (DFU), sponsored by ACECR. Primary endpoints: Local and systemic side effects and Complete healing rate. Started Mar 2019; status: completed.
02
Drugs
MSV alogénicas
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on IRCT20170612034485N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20170612034485N2.